Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2022 | Outperform → Perform | Oppenheimer | |
| 5/5/2022 | $34.00 → $25.00 | Overweight | Cantor Fitzgerald |
| 3/8/2022 | $30.00 → $22.00 | Outperform | SVB Leerink |
| 3/1/2022 | $31.00 → $27.00 | Outperform | RBC Capital |
| 2/23/2022 | $34.00 → $31.00 | Outperform | RBC Capital |
| 12/10/2021 | $33.00 → $31.00 | Perform → Outperform | Oppenheimer |
| 11/4/2021 | $32.00 → $33.00 | Perform | Oppenheimer |
| 11/4/2021 | $35.00 → $40.00 | Buy | HC Wainwright & Co. |
Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity
Oppenheimer downgraded Aurinia Pharma from Outperform to Perform
Cantor Fitzgerald resumed coverage of Aurinia Pharma with a rating of Overweight and set a new price target of $25.00 from $34.00 previously
SVB Leerink reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $22.00 from $30.00 previously
S-8 - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
10-Q - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)